Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from biotechnology

Congressional Panel Says the United States Is Losing Its Lead on Rare Disease Cures

A bipartisan congressional advisory commission identified four barriers keeping rare disease therapies from patients and urged an all-of-government response.

Medical Daily

At-home STI test pulled from Australian shelves after failing to detect infections

Exclusive: TGA finds Touch Biotechnology test for chlamydia and gonorrhoea ‘is not reliable’ and has affected an unspecified number of people

The Guardian - AU

6 Ayurvedic Herbs With Real Clinical Evidence: Ashwagandha, Turmeric, and More

Ashwagandha (Withania somnifera)The most clinically studied adaptogen in the Ayurvedic pharmacopoeia, ashwagandha has accumulated enough trial data to move beyond wellness-counter claims. A 2019 randomised, double-blind, placebo-controlled trial published in Medicine found that 240 mg of standardised ashwagandha root extract daily reduced serum cortisol by 23% over 60 days. Participants…

Times Life

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Changed Depression Care With Prozac. Now It's Betting on Psychedelics with AtaiBeckley Acquisition

Eli Lilly is making its biggest move yet into the rapidly evolving field of psychedelic medicine, acquiring clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion.

International Business Times

NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution

India's bioeconomy can reach USD 691 billion by 2035, creating millions of high-value jobs. The nation aims to become a top global biotechnology power, driving future growth. A roadmap proposes six National BioMissions and a significant growth fund for development. Talent development, including engineering biology courses, is deemed critical for…

The Economic Times

'The thing that's amazing to me is this was 3D-printed': Pentagon's SciTech supremo describes future of warfare where projectiles are made up of coconut husks and coffee grounds

The Ukraine war has fundamentally changed the Pentagon's science chief's understanding of the role of AI and biotechnology in future conflicts

TechRadar

Canada Clean Room Solutions for Controlled Testing

Manufacturers working in pharmaceutical, biotechnology, healthcare, and research sectors depend on controlled environments every day. A properly designed Canada clean room helps reduce contamination and supports consistent production quality. These facilities maintain strict limits for airborne particles, temperature, and humidity. As regulations continue to evolve, controlled spaces have become essential…

inkl

Read news from The Economist, FT, and more,
with one subscription

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

MarketBeat

EU ministers reach consensus on Biotech Act directive

Amid Europe’s push to catch up in the biotechnology field, the EU health ministers agreed how to tweak rules on modified micro-organisms (GMMs) and the processing of organs.

Euronews

Karnataka explores biotech financing framework, AI-led innovation to support sector growth

Karnataka is developing a dedicated support framework for its biotechnology sector, encompassing funding, mentoring, and regulatory guidance to boost startups and growth capital access. Key focus areas for the next phase of growth include AI-enabled biotechnology and biomanufacturing, aiming to strengthen the state's innovation and investment ecosystem.

The Economic Times

Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary

SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release of the 2025 Sustainability Report. Structured around four key themes—Stable Development, Strong Momentum, Green Ecosystem, and Warm Care—the report outlines the company's performance in food…

AAP

Is it possible to rejuvenate damaged human cells? US biotech firm tests new gene therapy

A US biotechnology company has tested a gene therapy designed to reverse ageing in humans for the first time.

Euronews

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 at the 14th World Congress for Hair Research (WCHR) in Seoul, South…

AAP

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Tech giants warn AI safety gaps could hand bioweapons to bad actors

Synthetic DNA can be used for vaccines, but it can also create bioweapons. Tech giants and biotechnology experts are asking for stronger regulation.

MarketBeat

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe

AAP

MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.

SEOUL, South Korea, June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a significant step forward in MEDIPOST's mission…

AAP

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

SAN CARLOS, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Therapeutic Goods Administration (TGA) of Australia granted approval with conditions of…

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

KrystoLens from Brain Navi Receives TFDA Certification, Set to Enter Taiwan Market

ZHUBEI, June 3, 2026 /PRNewswire/ -- Brain Navi Biotechnology announced that its KrystoLens, the single-use neuro-endoscope, has officially received certification from the Taiwan Food and Drug Administration (TFDA), marking an important milestone in the company's development in medical imaging and endoscopic applications.

AAP

FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test

SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals....

MarketBeat

MacroGenics Eyes $200M Cash Boost, 2028 Runway Ahead of Cancer Pipeline Updates

MacroGenics (NASDAQ:MGNX) Chief Executive Officer Eric Risser said the biotechnology company has strengthened its balance sheet through two recent transactions while preparing for a series of clinical updates across its oncology pipeline. Speaking during an informal discussion hosted by Stifel seni

International Business Times

Manish Singh's View of Oncology Innovation Through Clinical Insight and Long-Term Thinking

Dr. Singh's professional journey spans scientific research, venture investing, and biotechnology leadership, experiences that collectively shaped his perspective on how meaningful innovation occurs.

The Economic Times

Biotech startup StrainX Bioworks raises $13 million from Prime Venture, Leo Capital, others

StrainX Bioworks, a synthetic biology and precision fermentation startup, has raised $13 million to advance its biotechnology platform. The company, with a team of over 100 experts, aims to scale production to 100,000 litres and forge global partnerships, positioning India as a leader in biological manufacturing.

AAP

Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan

TAIPEI, May 22, 2026 /PRNewswire/ -- Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.

AAP

Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer

CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for the treatment of pancreatic cancer. The study,…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.